Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: A cross-sectional study

Rheumatology International

Volumn 32, Issue 9, 2012, Pages 2653-2660

  Rodŕguez Reyna, Tatiana S ^a   Furuzawa Carballeda, Janette ^a   Cabiedes, Javier ^a   Fajardo Hermosillo, Luis D ^a   Mart́nez Reyes, Cynthia ^a   D́az Zamudio, Mariana ^a   Llorente, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Scleroderma; Systemic sclerosis; Th1; Th17; Th2; Tregs

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CD4 ANTIGEN; COLCHICINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH1 CELL; TH17 CELL; TH2 CELL;

ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELL COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84866405411     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2056-y     Document Type: Article

References (29)

1. Piela TH, Korn JH (1988) Lymphocyte-fibroblast adhesion induced by interferon-c. Cell Immunol 114:149-160
2. Abraham D, Lupoli S, McWhirter A, Plater-Zyberk C, Piela TH, Korn JH et al (1991) Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 34:1164-1172
3. Yurovsky VV, Wigley FM, Wise RA, White B (1996) Skewing of the CD8 T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48:84-97 (Pubitemid 26238957)
4. Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148:32-46 (Pubitemid 46365005)
5. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2009) Human Th17 cells: are they different from murine Th17 cells? Eur J Immunol 39:637-640
6. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677-688 (Pubitemid 43867371)
7. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y et al (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and RPR gamma. Immunity 28:29-39
8. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y et al (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthriths Rheum 43:2455-2463
9. Scala E, Pallota S, Frezzolini A, Abeni D, Barbieri C, Sampogna F et al (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138:540-546 (Pubitemid 39573637)
10. Duncan MR, Berman B (1989) Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin 1-alpha and beta and tumor necrosis factor-alpha and beta 1. J Invest Dermatol 92:699-706 (Pubitemid 19143619)
11. Piguet PF, Vesin C, Grau GE, Thompson RC (1993) Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5:57-61 (Pubitemid 23098835)
12. Duncan MR, Berman B (1991) Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant interleukin 6. J Invest Dermatol 97:686-692
13. Bamber B, Reife RA, Haugen HS, Clegg CH (1998) Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease. J Mol Med 76:61-69 (Pubitemid 28085062)
14. Feghali CA, Bost KL, Boulware DW, Levy LS (1994) Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 17:309-318 (Pubitemid 24238337)
15. Hasegawa M, Sato S, Ihn H, Takehara K (1999) Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 38:612-617 (Pubitemid 29507328)
16. Deleuran B, Abraham DJ (2007) Possible implication of the effector CD4 T-cell subpopulation Th17 in the pathogenesis of systemic scleroderma. Nature Clin Practice Rheumatol 3:682-683 (Pubitemid 350187010)
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980). Arthritis Rheum 23:581-590
18. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowickz M, Boire G et al (2008) Autoantibodies and Microvascular damage are independent predictive factors for the progression of Raynaud0s phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients, with validation of proposed criteria early systemic sclerosis. Arthritis Rheum 58:3902-3912
19. Simera I, Moher D, Hoey J, Schulz KF, Altman DG (2010) A catalogue of reporting guidelines for health research. Eur J Clin Invest 40:35-53
20. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP Autoantibodies in Systemic Sclerosis. Arthritis Rheum 60:1112-1118
21. Furuzawa-Carballeda J, Llorente L, Cabiedes J, Fajardo-Hermosillo L, Vargas-Rojas MI, Rodriguez-Reyna TS (2009) Th17, Th1 and Treg subsets are increased in systemic sclerosis (SSc) patients. Clin Immunol 131(Suppl.1):S115
22. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGF-b and IFN-c distinguishes SSc phenotypes. Plos One 4:1-9 e5903
23. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK et al (2010) IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184:1526-1535
24. Kawaguchi Y, Hara M, Wright TM (1999) Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 103:1253-1260 (Pubitemid 29218295)
25. Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140-146 (Pubitemid 32781022)
26. Feghali CA, Bost KL, Boulware DW, Levy LS (1992) Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 19:1207-1211
27. Fiocco U, Rosada M, Cozzi L, Ortolani C, De Silvestro G, Ruffatti A et al (1993) Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 52:272-277 (Pubitemid 23103357)
28. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFb expression. Plos One 4:e5981
29. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J (2008) Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17:289-294 (Pubitemid 351655795)